Cadrenal Therapeutics Achieves Major Milestone with FDA Guidance for Pivotal Phase 3 Trial of CAD-1005 in HIT

Key Developments Set Stage for Potential First New HIT Therapy in Over 20 Years

PONTE VEDRA, FL, April 30, 2026 – Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) announced a significant regulatory achievement that could have major implications for the company’s future and its shareholders. After a successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), Cadrenal received critical guidance on the advancement of its lead product candidate, CAD-1005, for the treatment of heparin-induced thrombocytopenia (HIT). The FDA’s feedback has cleared the path for Cadrenal to proceed directly to a pivotal Phase 3 registration trial for CAD-1005, marking a crucial inflection point for the company’s clinical and regulatory strategy.

Key Points for Investors

• FDA End-of-Phase 2 Meeting Successful: The FDA provided detailed feedback on all critical elements necessary to design a pivotal Phase 3 trial. These include protocol design, patient population, dosing, background therapies, exposure, safety database, and the primary endpoint (centrally adjudicated incidence of new or worsening thrombotic events).
• Compelling Phase 2 Results: CAD-1005 demonstrated over a 25% absolute reduction in thrombotic events when added to standard anticoagulant therapy, a clinically meaningful outcome that supports its continued development.
• Planned Phase 3 Study Details:
  • The pivotal Phase 3 trial will be a randomized, blinded, placebo-controlled study enrolling approximately 120 patients with HIT, across up to 50 clinical centers worldwide.
  • Patients with suspected HIT will be randomized to receive CAD-1005 or placebo, in addition to standard-of-care anticoagulation, for up to 14 days during hospitalization.
  • The primary endpoint is centrally adjudicated incidence of new or worsening thrombotic events in patients with Serotonin Release Assay (SRA)-confirmed HIT.
  • At least one interim analysis is planned.
  • The trial is intended to support a projected New Drug Application (NDA) submission in 2029.
• Unmet Medical Need: HIT is a severe, immune-mediated complication of heparin therapy, with high rates of morbidity and mortality (over 20% in some studies). No new therapies have been approved in more than two decades, highlighting the potential market opportunity for CAD-1005.
• First-in-Class Mechanism: CAD-1005 is a first-in-class 12-lipoxygenase (12-LOX) inhibitor that targets the underlying immune mechanism of HIT, potentially setting it apart from existing treatments that address only thrombotic complications.
• Regulatory Advantages: CAD-1005 has received both Orphan Drug and Fast Track designations from the FDA, as well as orphan drug status from the European Medicines Agency, which may facilitate expedited development and market access.
• Broader Pipeline: Cadrenal is also developing second-generation 12-LOX oral therapeutics for chronic conditions and has late-stage programs for tecarfarin (an oral vitamin K antagonist for chronic anticoagulation) and frunexian (a parenteral Factor XIa inhibitor for acute hospital use).

Potential Impact on Shareholders and Stock Value

The announcement that Cadrenal is moving directly to a pivotal Phase 3 trial with FDA guidance is highly significant and potentially price-sensitive. Achieving this regulatory milestone de-risks the development pathway for CAD-1005 and positions the company to address a large, underserved market. Additionally, the promising Phase 2 data, combined with Orphan and Fast Track regulatory designations, could accelerate timelines and increase the likelihood of favorable outcomes in both the clinic and the market.

Investors should also note that the projected NDA submission is targeted for 2029, and successful completion of the planned trial could make CAD-1005 the first new therapy for HIT in over 20 years. However, the company’s ability to execute the trial, raise necessary funding, and achieve regulatory approval remains a key risk factor.

About Heparin-Induced Thrombocytopenia (HIT)

HIT is a dangerous immune-mediated reaction to heparin, the most widely used in-hospital anticoagulant (administered to over 12 million patients annually in the U.S.). It is characterized by antibody-mediated platelet activation, leading to life-threatening blood clots, low platelet counts, and increased bleeding risk. Complications can include deep vein thrombosis, pulmonary embolism, stroke, heart attack, limb amputation, and death.

About CAD-1005

CAD-1005 is an investigational therapy specifically designed to selectively inhibit 12-LOX, targeting the immune drivers of HIT rather than only blocking thrombotic complications. This unique approach distinguishes it from existing therapies and may offer improved outcomes for patients suffering from this devastating condition.

About Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is a late-stage biopharmaceutical company focused on developing novel therapies for immune and thrombotic diseases. In addition to CAD-1005, the company is advancing tecarfarin (for chronic anticoagulation) and frunexian (for acute hospital settings), further broadening its late-stage pipeline.

Investor Considerations and Forward-Looking Statements

While today’s announcement is a major milestone, investors should be aware that the outcome of the upcoming pivotal trial, NDA submission, and regulatory approval process remains uncertain. Success will depend on continued clinical progress, securing additional funding, and navigating regulatory requirements.

Disclaimer: This article is for informational purposes only and is not investment advice. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those anticipated. Investors are urged to review the company’s filings with the SEC and consult with their own financial advisors before making investment decisions.

View Cadrenal Therapeutics, Inc. Historical chart here